{"filings":[{"id":723997,"accession_number":"0001919246-26-000085","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-05-28T21:01:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pelthos Therapeutics CEO to present at Jefferies conference; no material news disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Scott Plesha will present at 11:05 a.m. ET on June 4, 2026 at the Jefferies Global Healthcare Conference in New York.","The company will also hold one-on-one investor meetings at the conference.","No financial results, guidance, or other material corporate developments were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":583961,"accession_number":"0001919246-26-000078","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-05-21T21:00:16+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"Pelthos Therapeutics dismisses CFO Knuettel, appoints Grant Thornton as auditor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Francis Knuettel II terminated effective April 10, 2026; separation agreement provides $430,000 severance (12 months salary) and accelerated vesting of 59,500 options and 19,525 RSUs.","Auditor change: CBIZ CPAs dismissed, Grant Thornton LLP engaged for FY2026; no disagreements or reportable events reported.","Knuettel's equity acceleration: 59,500 options and 19,525 RSUs vest; options exercisable until Jan 15, 2027, unvested portion forfeited.","Separation agreement includes release of claims, confidentiality, non-disparagement, and cooperation; effective after 7-day revocation period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77481,"accession_number":"0001919246-26-000071","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-05-14T11:08:04+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pelthos Therapeutics Q1 2026 ZELSUVMI net revenue $10.7M, up 17% QoQ; net loss $10.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZELSUVMI net product revenue $10.7M in Q1 2026, up 17% from $9.1M in Q4 2025; units dispensed 7,884 (+25% QoQ).","Net loss of $(10.2)M vs $(21.7)M in Q4 2025; adjusted EBITDA $(8.0)M.","Cash $32.0M as of March 31, 2026; drew $30M from $50M Horizon term loan facility in January 2026.","Sales force expanded to 64 territory managers from 50; April units 3,776; cumulative >20,000 since July 2025 launch.","Planned commercialization of XEPI in early 2027 and XEGLYZE in mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":10906000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96729,"accession_number":"0001919246-26-000060","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CEO Scott Plesha to attend Piper Sandler Spring Biopharma Symposium on April 16, 2026","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO will hold one-on-one investor meetings at conference in Boston.","Corporate presentation made available on company website but contains no new material disclosures.","No financial results, pipeline updates, or material events announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96728,"accession_number":"0001919246-26-000058","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pelthos Therapeutics appoints John M. Gay as CFO, replaces Francis Knuettel II","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John M. Gay appointed CFO effective April 10, 2026; also named treasurer and secretary.","Gay previously served as SVP, Finance & Accounting since July 2025; prior CFO at LNHC and Novan.","Francis Knuettel II terminated as CFO effective April 10, 2026; no disagreement cited.","Gay's employment agreement: $425,000 base salary, 40% target annual bonus.","Press release issued April 10, 2026; CEO Scott Plesha cites strong commercial momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110895,"accession_number":"0001919246-26-000014","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pelthos Q4 ZELSUVMI sales $9.1M, up 28% QoQ; adds XEPI and XEGLYZE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZELSUVMI net product revenue $9.1M in Q4 2025 vs $7.1M in Q3; full-year 2025 total revenue $16.8M.","8,948 units dispensed, 2,712 unique prescribers; Q4 units up 129% QoQ to 6,232.","Acquired XEPI (impetigo) Nov 2025 and XEGLYZE (head lice) Jan 2026; sales force expanded to 64.","Closed $18M convertible notes Nov 2025 and $50M term loan ($30M drawn) Jan 2026; cash $18M at year-end.","Operating loss improved to $12M in Q4 from $15.4M in Q3; adjusted EBITDA loss improved 22% QoQ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110894,"accession_number":"0001753926-26-000097","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Pelthos secures up to $50M senior secured term loan from Horizon; $30M drawn at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $50M senior secured term loan facility from Horizon Technology Finance; $30M funded at closing on Jan 12, 2026.","Remaining $20M available upon achieving milestones; interest rate prime +3.75% (currently 10.50%) with 6.75% floor.","Proceeds to commercialize ZELSUVMI, launch Xepi and Xeglyze, and for working capital.","Issued warrants for 65,488 shares at $27.49 per share to Horizon; loan matures Jan 31, 2031.","As of Sept 30, 2025, cash and investments $14.2M; augmented by $18M convertible notes in Nov 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110893,"accession_number":"0001753926-26-000094","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Pelthos Therapeutics revises non-employee director compensation, increases Chairman cash retainer to $60k","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Non-Executive Chairman annual cash retainer increased from $50k to $60k, effective January 1, 2026.","New annual cash retainers for committee service: Audit Chair $19k, Compensation Chair $15k, Nominating Chair $12k.","Board member annual cash retainer unchanged at $40k; no annual equity grants to non-employee directors.","Changes based on compensation committee assessment to align with peer group practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110892,"accession_number":"0001753926-26-000010","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Pelthos Therapeutics acquires Xeglyze (abametapir) head lice treatment for $1.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $1.8M; $450K deposit paid Nov 20, 2025, $1.35M paid at closing Dec 23, 2025.","Xeglyze is FDA-approved (Jul 2020) for head lice in patients 6 months+; single 10-minute application.","No future milestone, royalty, or other payments owed to Hatchtech; worldwide commercialization rights.","Pelthos plans to relaunch Xeglyze in first half of 2027.","CEO Scott Plesha says acquisition aligns with strategy of commercializing innovative products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127519,"accession_number":"0001753926-25-001964","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Pelthos Therapeutics appoints Andrew Einhorn to Board of Directors; board expands to eight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Einhorn appointed to Board effective December 23, 2025, filling newly created eighth seat.","Einhorn will serve on Audit and Compensation Committees; term until 2026 annual meeting.","Einhorn brings 40+ years of finance, capital markets, and life sciences experience.","Granted 12,000 RSUs vesting January 1, 2027, plus standard non-employee director compensation.","Board expanded from seven to eight members; Einhorn deemed independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127518,"accession_number":"0001753926-25-001906","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pelthos Therapeutics shareholders elect directors, approve waiver of convertible note share limit, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with >2.24M 'For' votes each; broker non-votes of 278,134.","Shareholders approved waiver of share issuance limit under senior secured convertible notes (For 2,247,248, Against 3,474).","Ratified CBIZ CPAs as independent auditor for fiscal year ending Dec 31, 2025 (For 2,509,765, Against 19,091)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127517,"accession_number":"0001753926-25-001766","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pelthos Q3: ZELSUVMI launch generates $7.1M net revenue, net loss $16.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $7.1M from ZELSUVMI in first commercial quarter (Q3 ended Sep 30, 2025).","2,716 units prescribed by 1,169 unique prescribers; October alone saw 2,189 units prescribed.","Net loss of $16.2M ($5.30 per basic/diluted share); as-converted net loss of $1.83/share.","Cash of $14.2M at Sep 30, 2025; closed $18M convertible notes financing in Nov 2025.","Completed acquisition of XEPI (FDA-approved impetigo treatment) in Nov 2025, adding complementary dermatology product."],"consensus_eps_estimate":-0.4386,"consensus_eps_actual":-14.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":7406000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127516,"accession_number":"0001753926-25-001715","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Pelthos raises $18M via convertible notes; acquires Xepi from Biofrontera","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $18.0M aggregate 8.5% senior secured convertible notes due Nov 2027; conversion price $34.442/sh (adjustable to $29.73 on shareholder approval).","Acquired Xepi (ozenoxacin) cream from Biofrontera for up to $10M: $3M cash upfront, $1M conditional, $6M milestone payments.","Entered Ferrer License Agreement for exclusive manufacture/commercialization of Xepi in US; 12-year initial term.","Granted investors 5% royalty on Xepi net sales and rights to Sato/ZELSUVMI milestone payments under convertible note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127515,"accession_number":"0001753926-25-001606","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Pelthos Therapeutics posts corporate presentation; no specific material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation for Q4 2025 made available on company website on October 14, 2025.","No financial results, guidance, or product-specific updates provided in the filing text.","The exhibit text is truncated, precluding identification of any material developments.","Presentation furnished under Regulation FD and not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144306,"accession_number":"0001753926-25-001500","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K/A","filed_at":"2025-09-16T23:59:59+00:00","items":["9.01","2.01","2.02"],"status":"ready","headline":"Pelthos (PTHS) files LNHC unaudited financials and pro forma data post-merger closed July 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger closed July 1, 2025; issued ~31,278 Series A Preferred shares to Ligand; PIPE raised ~$50.1M gross.","LNHC unaudited balance sheets as of June 30, 2025 and 2024; pro forma financial info provided for combined entity.","ZELSUVMI (berdazimer gel) FDA approved Jan 2024 for molluscum contagiosum; 13% royalty to Ligand on worldwide sales.","Nomis RoyaltyVest receives 1.5% royalty on ZELSUVMI net sales; additional royalty agreements with Ligand and Madison.","Company holds exclusive license from Ligand for ZELSUVMI ex-Japan; 19,265 sq ft facility in Durham, NC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144309,"accession_number":"0001753926-25-001425","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pelthos Therapeutics to present at Wells Fargo 2025 Healthcare Conference on Sept 3","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Scott Plesha and CFO Frank Knuettel to present at Wells Fargo Healthcare Conference on Sept 3, 2025 at 1:30 pm ET.","Company to provide pipeline update and discuss commercial launch of ZELSUVMI (berdazimer) for molluscum contagiosum.","Webcast and replay available on company's website for 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144308,"accession_number":"0001753926-25-001353","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pelthos Therapeutics completes merger, launches ZELSUVMI, hires 50 sales managers","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Completed merger with Channel Therapeutics and closed $50.1M private placement on July 1, 2025.","Launched ZELSUVMI (berdazimer) on July 10, 2025, first at-home FDA-approved treatment for molluscum contagiosum.","Built commercial team of 90+ employees including 50 territory sales managers; early orders and prescriptions meeting/exceeding expectations.","In advanced discussions to acquire a second FDA-approved pediatric infectious disease product.","Public float ~600k shares; market cap ~$55M (~$165M fully diluted); lockup on Series A Preferred through Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144307,"accession_number":"0001753926-25-001055","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","3.03","5.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Pelthos Therapeutics closes merger with LNHC, raises $50.1M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed merger with LNHC (Ligand subsidiary) on July 1, 2025; LNHC shareholders own ~55.8% on fully diluted basis.","Raised ~$50.1M in PIPE financing via Series A Preferred Stock at $1,000/share; Ligand participated.","Effected 1-for-10 reverse stock split and changed name to Pelthos Therapeutics; ticker changes to PTHS on NYSE American.","Appointed Scott Plesha as CEO/President; Francis Knuettel remains CFO; added four new directors to board.","Entered royalty sale agreements for ZELSUVMI and other products with Nomis, Ligand, and Madison."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162663,"accession_number":"0001753926-25-000722","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Channel Therapeutics issues NYSE American-required announcement on going concern in 2024 10-K","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["2024 10-K audit opinion includes a going concern emphasis of matter (previously filed March 27, 2025).","Press release issued May 1, 2025 to comply with NYSE American Sections 401(h) and 610(b).","Announcement does not change or amend the audited financial statements or the 2024 10-K.","Company develops non-opioid pain therapeutics (no new business updates)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162662,"accession_number":"0001753926-25-000652","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["1.01","3.02","4.01","5.07","7.01","8.01","9.01"],"status":"ready","headline":"Channel Therapeutics to merge with LNHC in reverse merger; Ligand to own ~55%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["LNHC valued at $67M; Channel at $15M; combined entity renamed Pelthos Therapeutics Inc.","Post-closing ownership: legacy CHRO 7.7%, Ligand 55.1%, other PIPE investors 37.2%.","PIPE financing of $50.1M from Ligand, Nomis Bay, others; convertible at $1.00/share.","New board includes Scott Plesha (CEO), Francis Knuettel II (CFO); lock-up until Dec 31, 2025.","Auditor changed from Marcum to CBIZ; material weaknesses in internal controls continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180652,"accession_number":"0001753926-25-000376","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Channel Therapeutics issues $325K promissory note to 3i, L.P. at $250K purchase price","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $325,000 principal unsecured note to 3i, L.P. for $250,000 purchase price (approx. 23% discount).","Interest at 6.0% simple p.a.; maturity on May 25, 2025 or upon Corporate Event or default.","Prepayable without penalty on 2 days' notice; proceeds for general working capital.","Note is unsecured; contains standard Events of Default and no stockholder rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197469,"accession_number":"0001753926-24-001983","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chromocell renamed Channel Therapeutics, reincorporates in Nevada; pipeline milestones expected soon","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Name change to Channel Therapeutics effective Nov 18, 2024; reincorporation in Nevada for lower taxes and strategic flexibility.","Depot program for postoperative nerve blocks: sustained drug release over 96 hours in animals; efficacy results imminent.","Eye pain program: drops well tolerated in animals; efficacy results in weeks, toxicology data late Q1 2025, Phase II in Q2 2025.","Chronic pain program exploring program-specific financing; kickoff expected in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197467,"accession_number":"0001753926-24-001960","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K12G3","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","2.03","3.03","5.02","5.03","9.01"],"status":"ready","headline":"Channel Therapeutics completes reincorporation from Delaware to Nevada; stockholder rights change","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Chromocell Therapeutics merged into wholly-owned Nevada subsidiary Channel Therapeutics; all shares converted 1:1.","Company name changed to Channel Therapeutics Corporation; ticker remains CHRO on NYSE American.","Governing law shifts from DGCL to NRS; stockholder rights may differ as described in proxy statement filed Sept 26, 2024.","Existing directors and officers remain; all prior liabilities assumed by Nevada corporation.","Indemnification agreements updated to reflect Nevada law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197468,"accession_number":"0001753926-24-001955","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","2.03","3.03","5.02","5.03","9.01"],"status":"ready","headline":"Chromocell reincorporates as Nevada corporation Channel Therapeutics; shares convert 1:1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Nov 18, 2024, Chromocell Therapeutics (Delaware) merged into its Nevada subsidiary, Channel Therapeutics Corp, as the surviving entity.","Each outstanding share of Chromocell common stock converted into one share of Channel Therapeutics common stock (same symbol CHRO).","The reincorporation was approved by a majority of stockholders at the Oct 22, 2024 Annual Meeting; board and officers remain unchanged.","Stockholder rights may be affected by differences between Nevada Revised Statutes and Delaware General Corporation Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197470,"accession_number":"0001753926-24-001759","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Shareholders approve reincorporation to Nevada and name change to Channel Therapeutics; board adds $500k to buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 4 approved: reincorporation from Delaware to Nevada and renaming to Channel Therapeutics Corp. (2.6M for, 2.3K against, 929.7K abstain).","Board authorizes amendment to repurchase plan: adds $500k (total $750k) and extends termination to June 30, 2025.","Proposal 1: all five director nominees elected (Todd Davis, Ezra Friedberg, Francis Knuettel II, Dr. Richard Malamut, Chia-Lin Simmons).","Proposal 2: amendment to 2023 Equity Incentive Plan increasing authorized shares approved (3.5M for).","Proposal 5: Marcum LLP ratified as independent auditor for FY2024 (3.9M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213709,"accession_number":"0001753926-24-001376","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chromocell authorizes $250K stock repurchase plan; up to ~23% of non-affiliate float","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized repurchase of up to $250,000 of common stock, representing ~23% of non-affiliate float.","Repurchases may occur via open market or private transactions through Dec 31, 2024.","CEO states stock price does not reflect progress in developing non-opioid pain treatments.","Plan does not obligate company to repurchase any shares; may be modified or terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213708,"accession_number":"0001753926-24-001275","cik":1919246,"company_name":"Pelthos Therapeutics Inc.","ticker":"PTHS","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Chromocell raises $750k via convertible note and secures $30M committed equity facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$750k convertible note issued, 6% interest (12% default), convertible at $1.506/share, floor $0.231, maturity Aug 24, 2025.","Committed equity facility with Tikkun Capital for up to $30M; shares sold at 90% of VWAP over up to 24 months.","$750k commitment fee paid to Tikkun; $75k legal fees reimbursed; restrictions on variable rate transactions.","Stockholder approval required to exceed exchange cap; meeting within 90 days for note; similar cap for equity facility.","Proceeds to fund clinical work on CC8464 and CT2000 compounds and for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":91409462.32937686,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}